Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has a very high sensitivity in detecting breast cancer, but it often leads to unnecessary biopsies and patient workup. In this paper, we used an artificial intelligence (AI) system to improve the overall accuracy of breast cancer diagnosis and personalize management of patients undergoing DCE-MRI. On the internal test set (N=3,936 exams), our system achieved an area under the receiver operating characteristic curve (AUROC) of 0.92 (95% CI: 0.92-0.93). In a retrospective reader study, there was no statistically significant difference between 5 board-certified breast radiologists and the AI system (mean ΔAUROC +0.04 in favor of the AI system). Radiologists’ performance improved when their predictions were averaged with AI’s predictions (mean ΔAUPRC [area under the precision-recall curve] +0.07). Those hybrid predictions also increase interreader agreement (Fleiss’ kappa Δ +0.21 (0.16-0.26)). We demonstrated the generalizability of the AI system using multiple data sets from Poland and the US. In subgroup analysis, we observed consistent results across different cancer subtypes and patient demographics. Using the decision curve analysis, we showed that the AI system can reduce unnecessary biopsies in the range of clinically relevant risk thresholds. This would lead to avoiding benign biopsies in up to 20% of all BI-RADS category 4 patients. Finally, we performed an error analysis, investigating situations where AI predictions were mostly incorrect. This exploratory work creates a foundation for deployment and prospective analysis of AI-based models for breast MRI.
One Sentence Summary We developed and evaluated an AI system for predicting breast cancer in MRI that matches the performance of board-certified radiologists and has the potential to prevent unnecessary biopsies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by grants from the National Institutes of Health (P41EB017183, R21CA225175) and the Gordon and Betty Moore Foundation (9683). JW was supported in part by The Iwanowska Programme from the Polish National Agency for Academic Exchange (PPN/IWA/2019/1/00114/U/00001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NYU Langone Health Institutional Review Board approved this retrospective study (ID #s18-00712). Informed consent requirement was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our internal (NYU Langone Health) data set is not publicly available due to internal data transfer policies. We released a data report on data curation and preprocessing to encourage reproducibility. The data report can be accessed at https://cs.nyu.edu/~kgeras/reports/MRI_datav1.0.pdf. The Jagiellonian University data set has been acquired for NYU Langone Health researchers through a data transfer agreement, and is not publicly available. Duke Breast Cancer MRI and TCGA-BRCA are publicly available in the Cancer Imaging Archive.
